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A B S T R A C T
Osteoporosis is a systemic disease, which is characterized by reduced bone mass and microarchitectural deterioration
of the bone tissue, resulting in an increased risk of fracture. Since osteoporosis is today a disease with high incidence
rate, the aim of this study was to determine a correlation between bone mass density (BMD) and concentration of bio-
chemical bone turnover markers – deoxypyridinoline (DPD) as a marker of bone resorption, and osteocalcin (OC) as a
marker of bone formation. The study included 70 women between 33 and 76 years of age. In all women BMD was mea-
sured by Dual X-ray Absorptiometry (DXA) as a T-score. T-score was defined as the number of standard deviations of the
bone mass density from the maximum bone mass density in young adults. According to T-score, patients were divided
into three groups: patients with osteoporosis, patients with osteopenia and control group consisting of patients with nor-
mal T-score. DPD in urine and OC in serum were measured by a routine procedure. Results: a negative correlation be-
tween BMD and concentration of bone turnover marker was discovered. One-way analysis of variance and Pearson corre-
lation were used for statistical analysis, with a P value <0.05 being considered significant. Although a negative correlation
was discovered, we concluded that both procedures have a significant role in diagnosis and follow-up of patients with os-
teoporosis.
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Introduction
Osteoporosis is a systemic disease, which is character-
ized by a low bone mass and microarchitectural deterio-
ration of the bone tissue, resulting in an increased risk of
fracture1. Remodeling processes are conducted in bone
tissue during a lifetime, i.e. bone resorption and bone for-
mation processes, which are in balance in healthy tissue.
A prolonged imbalance in bone metabolism between bone
resorption and formation, with bone resorption exceed-
ing formation, may result in increased bone fragility2,3.
Bone Mass Density (BMD) is measured by densitometry,
most commonly by Dual X-ray Absorptiometry (DXA).
The most valuable parameter in DXA is T-score. T-score
is defined as the number of standard deviations of the
bone mass density from the maximum bone mass density
in young adults. World Health Organization (WHO) has
defined diagnostic criteria for osteoporosis based on
T-score where T-score between –1.0 and –2.5 is defined as
osteopenia and T-score below –2.5 is defined as osteo-
porosis4.
Bone formation and resorption data can be achieved
by measuring biochemical markers of bone turnover
(BTMs) in serum and urine. According to the literature
search, BTMs may be useful as: screening method, diag-
nostic criteria, assessment of the stage of disease or risk
factors assessment, and documentation of effects of ther-
apeutic agents or determination of therapy initiation5.
By assessing the diagnostic value of BTMs in female pa-
tients with suspected osteoporosis, we have studied cor-
relation between the BMD and concentrations of deoxy-
pyridinoline (DPD) and osteocalcin (OC).
We have measured concentrations of two biochemical
bone turnover markers, DPD as a marker of bone resorp-
tion and OC as a marker of bone formation and com-
pared them to the BMD results. Osteocalcin is consid-
ered to be a specific marker for osteoblast function and is
the main noncolagen protein of the bone matrix. Osteo-
calcin is synthesized by osteoblasts, odontoblasts, and
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hypertrophic chondrocytes. After synthesis, which is sig-
nificantly stimulated by calcitriol, it binds to hydroxy-
apatite, and much of it is deposited in the bone matrix. A
smaller component of newly synthesized osteocalcin frag-
ments are released from the bone matrix into circulation
where its concentration can be measured by assays for
circulating osteocalcin6,7.
Pyridinoline (PYD; hydroxylysylpyridinoline) and deo-
xypyridinoline (DPD; lysylpyridinoline) are two non-re-
duced, cross-linked molecules of pyridine in mature bone
collagen. By resorption of the collagen, DPD molecules
are secreted into circulation and excreted in urine, either
as free or as peptide bound moieties6,7.
Materials and Methods
Study population
The study included 70 women between 33 and 76
years of age with suspected osteoporosis. Patients were
included in the study on their initial visit to the Clinical
Department of Nuclear Medicine and Radiation Protec-
tion – Reference Centre of the Ministry of Health and So-
cial Welfare of the Republic of Croatia, Division for Diag-
nosing Parathyroid Gland Diseases. Concentration of
DPD in urine and OC in serum was measured in all
women.
Urine and blood sampling and analysis
Second morning urine sample was collected and DPD
in urine was measured. Sample was collected in the
morning after a patient urinated first at home and then
again in the hospital around 8 am into a special canister.
Urine samples were divided into 1 mL aliquots and saved
for competitive enzyme immunoanalisys of DPD by com-
mercially available kit, according to Manufacturer’s pro-
tocol (Metra Biosystem INC., Mountain View, SAD).
Reference values of DPD for women: 3.0–7.4 nM
DPD/mM creatinine and for men: 2.3–5.4 nM DPD/mM
creatinine. OC was measured in a serum of patients after
an overnight fasting, drinking only water. 8 mL of vein
blood was collected and stored immediately on ice to pre-
vent sample degradation. After 15 to 30 minutes sample
was coagulated, centrifuged and analyzed by immunora-
diometric method (IRMA) with commercially available
kits, according to Manufacturer’s recommendations (Bio-
Source Europe S.A., Nivelles, Belgium, reference value
of OC: 5–25 ng/mL).
Densitometry analysis
Bone Mass Density (BMD) was measured by Dual
X-ray Absorptiometry (DXA) at the Department of Endo-
crinology in the scope of the Clinic for Internal Diseases
at the University Hospital Centre Osijek.
Statistical analysis
One-way analysis of variance and Pearson correlation
were used for statistical analysis, with a p value <0.05
being considered significant.
Results
According to T-score, patients were divided into three
groups: patients with osteoporosis, patients with osteo-
penia and control group consisting of patients with nor-
mal T-score. Osteopenia (Table 1) was discovered in
44.28% of patients. In this group DPD was normal in
45.17% and increased in 54.83% of patients. OC concen-
trations were normal in 80.65%, increased in 6.45% and
decreased in 12.9% of patients with osteopenia. Osteopo-
rosis (Table 2) was discovered in 32.85% of patients. In
patients with osteoporosis DPD was normal in 39.14 % of
patients, increased in 56.52% and decreased in 4.34% of
patients. In the same group of patients, OC was normal
in 91.13 % and decreased in 8.69% of patients. Control











1 64 5.41 10.60 –1.9
2 65 4.30 7.94 –1.3
3 68 11.18 5.02 –1.3
4 54 10.85 21.3 –2.0
5 65 6.42 4.96 –2.3
6 71 5.31 9.25 –2.3
7 68 12.35 7.10 –2.1
8 63 12.36 5.87 –1.9
9 63 10.14 16.30 –2.3
10 58 3.09 1.30 –2.4
11 58 13.42 25.40 –1.3
12 73 6.50 4.26 –1.6
13 54 13.59 16.50 –2.4
14 70 13.48 11.60 –1.6
15 48 10.31 16.20 –2.3
16 57 5.06 8.60 –2.0
17 67 6.57 5.16 –2.3
18 69 5.51 27.90 –1.7
19 73 10.33 4.21 –1.9
20 33 6.17 5.72 –1.0
21 59 4.10 6.77 –1.9
22 48 12.86 8.51 –1.6
23 64 6.08 9.57 –2.0
24 72 6.18 11.90 –2.3
25 73 5.38 13.30 –1.5
26 76 12.26 14.70 –2.3
27 65 10.40 17.90 –1.6
28 58 12.80 19.90 –1.9
29 52 13.01 11.90 –2.1
30 53 8.36 9.16 –2.4
31 59 8.19 19.10 –2.0
group (Table 3) consisted of 22.85% of patients. DPD was
normal in 47.75% and increased in 56.25% of the control
group. OC was normal in 93.75% of the control group,
whereas it was decreased in only 6.25%. All patients have
signed consent on being informed before being included
in the study.
Discussion and Conclusion
This study has shown a negative correlation between
biochemical markers of the bone turnover and BMD.
Negative correlation has been established for DPD, as
well as for OC. DPD was increased in about a half of the
patients, whereas OC values were in the range of refer-
ential values in patients with osteoporosis, as well as in
patients with osteopenia. Data obtained in this study are
consistent with previous reports where the relationship
between markers and BMD was either not established,
or where a very weak correlation was established8–11.
These studies analyzed a larger number of biochemical
markers of the bone turnover. However, there are also
different data published, in which a positive correlation
between biochemical markers of the bone turnover and
BMD has been established12. Although data published in
different studies are contradictory, biochemical markers
of the bone turnover still play an important role in diag-
nosis, treatment and follow-up of osteoporosis. It has
also been established that levels of biochemical markers
of the bone turnover are important factor for identifying
the response of the bone tissue after starting with the
therapy13,14. Also, it is known that reduced levels of re-
sorption markers can occur even two weeks after the be-
ginning of bisphosphonate therapy and concentration
plateau can be reached after 3 to 6 months. Reduced lev-
els of bone formation markers occur somewhat later9,10.
Moreover, bone turnover markers can be a useful tool in
predicting a risk of future osteoporotic fractures14–20,
what is very important for women excluded from the
fragile bone risk group based on DXA results. In general,
measurement of biochemical bone turnover markers has
its advantages and disadvantages. Advantages include
identification of the rapid bone loss, weekly evaluation of
responses to therapy, as well as monitoring the results of
the therapy. Disadvantages include lack of consensus in
regard to constitution of high and low risk groups for
fracture occurrence, poor relationship between BMDmea-
surements and concentration of bone turnover markers
and expenses of measuring bone turnover markers, which
could also be a limiting factor. Also, disadvantages could
be variations in measurement of bone resorption mark-
ers, because their concentrations are affected by age,
menopause, occurrence of previous fractures and bone
size21–28. One of the limiting factors in detection of bone
turnover marker concentration is also inability to asses a
total bone loss and to predict future bone loss9. However,
regarding all these issues and because of the high inci-











1 65 5.34 14.80 –2.7
2 73 1.65 1.95 –3.4
3 56 9.94 12.00 –2.5
4 64 18.05 14.80 –3.3
5 53 4.91 11.60 –3.2
6 72 11.25 18.90 –4.8
7 70 11.36 19.40 –3.3
8 59 5.84 6.86 –2.8
9 58 12.16 16.40 –3.5
10 54 13.28 13.00 –3.8
11 75 9.03 12.20 –3.0
12 69 12.97 14.70 –4.5
13 68 10.03 21.30 –2.7
14 59 6.04 8.01 –2.6
15 73 4.54 7.56 –3.3
16 51 11.54 13.80 –3.8
17 55 12.99 13.40 –2.8
18 70 4.90 8.80 –3.0
19 75 3.84 7.95 –4.3
20 67 9.71 14.40 –3.5
21 54 7.33 11.20 –3.0
22 62 5.17 5.64 –2.7
23 67 8.94 2.54 –3.0
TABLE 3








1 57 6.93 10.90 0.4
2 58 4.75 7.31 2.8
3 37 5.71 5.97 –0.1
4 51 5.71 11.20 2.1
5 41 4.26 6.41 0.7
6 55 6.02 12.00 0.2
7 71 6.00 5.78 1.0
8 54 14.40 15.80 0.0
9 63 8.09 19.30 0.0
10 71 9.83 4.36 0.4
11 57 8.05 5.13 2.4
12 59 12.65 12.50 –0.6
13 51 10.32 7.43 –0.6
14 54 8.54 15.00 0.2
15 57 16.79 12.80 0.1
16 73 14.40 14.50 0.0
dence rate of osteoporosis in general population29–34 and
associated bone fracture risk, future plan is to conduct a
similar study with larger number of participants in-
cluded in the study and to measure a larger number of
biochemical bone turnover markers.
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DIJAGNOSTI^KA VRIJEDNOST BIOKEMIJSKIH MARKERA KO[TANE PREGRADNJE U
BOLESNICA SA SUMNJOM NA OSTEOPOROZU
S A @ E T A K
Osteoporoza je sistemska bolest koju karakterizira smanjenje ko{tane mase i propadanje mikroarhitekture ko{tanog
tkiva, a posljedica je pove}an rizik od nastanka fraktura. Kako je osteoporoza danas vrlo ra{irena bolest, svrha istra-
`ivanja bila je ustanoviti korelaciju izme|u gusto}e ko{tane mase (BMD – Bone Mass Density) i koncentracija bio-
kemijskih markera ko{tane pregradnje – deoksipiridinolina (DPD) kao markera ko{tane razgradnje i osteokalcina (OC)
kao markera formiranja kosti. Istra`ivanje je provedeno u 70 `ena dobi izme|u 33 i 76 godina. U svih `ena denzito-
metrijskim mjerenjem (DXA – Dual X-ray Absorptiometry) BMD izra`ena je s T-vrijedno{}u. T-vrijednost je broj stan-
dardnih odstupanja ko{tane gusto}e od maksimalne ko{tane mase mladih odraslih osoba. S obzirom na T-vrijednost,
bolesnice su podijeljene u dvije skupine: bolesnice s osteopenijom i bolesnice s osteoporozom. Kontrolnu skupinu ~inile
su ispitanice s urednom T-vrijednosti. Odre|ene su vrijednosti biokemijskih markera ko{tane pregradnje, DPD-a u
urinu i OC-a u serumu. Rezultati istra`ivanja ukazuju na negativnu korelaciju izme|u BMD-a i koncentracija nave-
denih biokemijskih markera ko{tane pregradnje. U stastisti~koj analizi kori{teni su jednostrana analiza verijance i
Pearsonov korelacijski test s pragom signifikantnosti p<0,05. Unato~ dobivenoj negativnoj korelaciji izme|u DPD-a i
OC-a i BMD-a, mi{ljenja smo da odre|ivanja koncentracija markera ko{tane razgradnje i formiranja kosti imaju zna~aj-
nu ulogu u dijagnostici i pra}enju bolesnika s osteoporozom.
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